- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00034255
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients
June 23, 2005 updated by: GMP Endotherapeutics
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of intramuscular INGAP Peptide given for the first time in humans as a potential treatment for diabetes.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment
62
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92161
- VASDHS Medical Center
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20003
- MedStar Research Institute - Clinical Research Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27713
- UNC Diabetes, Endocrinology, Metabolism Clinic
-
-
Texas
-
San Antonio, Texas, United States, 78284
- Texas Diabetes Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patients meeting all of the following inclusion criteria at screening can be considered for admission to the study.
Stage 1 and Stage 2:
- Male and female patients with, type 1 diabetes mellitus that are 18 through 70 years of age, or type 2 diabetes mellitus that are 30 through 70 years of age.
- Patients who are insulin deficient and are diagnosed with type 1 or type 2 diabetes mellitus, and are currently well managed with insulin, with or without metformin.
- Patients who have been on stable doses of insulin treatment for 90 days prior to study randomization.
Exclusion Criteria:
Patients meeting any of the following exclusion criteria at screening will not be enrolled in the study:
- Patients with a history of any clinically significant retinopathy, symptomatic autonomic neuropathy, unstable angina, or kidney problems.
- Patients with an uncontrolled or untreated significant pulmonary, neurological condition, or cardiovascular disease, including hypertension, congestive heart failure, angina, or peripheral vascular disease.
- Patients who have received any investigational product within 30 days of admission into the study.
- Patients with a history or clinical evidence of multiple organ autoimmune disorders.
- Patients with a medical condition, serious intercurrent illness, or extenuating circumstance that would significantly decrease study compliance, including all prescribed follow-up.
- Patients who are lactating and breastfeeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2001
Study Registration Dates
First Submitted
April 24, 2002
First Submitted That Met QC Criteria
April 24, 2002
First Posted (Estimate)
April 25, 2002
Study Record Updates
Last Update Posted (Estimate)
June 24, 2005
Last Update Submitted That Met QC Criteria
June 23, 2005
Last Verified
June 1, 2003
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INGAP-01-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on INGAP Peptide
-
Exsulin CorporationCompletedDiabetes Mellitus, Insulin-DependentUnited States
-
Jewish General HospitalCompletedType 1 Diabetes MellitusCanada
-
Exsulin CorporationTerminatedType 1 Diabetes MellitusUnited States, Canada
-
Exsulin CorporationCompletedDiabetes Mellitus, Non-Insulin-DependentUnited States
-
HighTide Biopharma Pty LtdCompleted
-
EgymedicalpediaCompleted
-
Xequel Bio, Inc.CompletedWound HealSwitzerland
-
Wuerzburg University HospitalCompleted
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Ewing's SarcomaUnited States
-
University of YamanashiHuman Genome Center, Institute of Medical Science, University of TokyoUnknownEsophageal CancerJapan